ocular inflammation

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. Upon ophthalmic administration, bromfenac binds to and inhibits cyclooxygenase II (COX II), an enzyme that converts arachidonic acid to cyclic endoperoxides, which are prostaglandin (PG) precursors. By inhibiting PG formation, bromfenac prevents PG-induced inflammation, vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, increased vascular permeability, and elevated intraocular pressure (IOP).

Difluprednate (Myser)(Durezol) is a corticosteroid, approved for the treatment of post-operative ocular inflammation and pain.

Flavanone hydrazine is a potent non-steroidal anti-inflammatory agent that effectively inhibits lens protein–induced ocular inflammation.

Ketorolac (RS37619) hydrochloride is a nonsteroidal anti-inflammatory drug and a non-selective COX inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in a 0.5% ophthalmic solution format for the investigation of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and post-operative ocular inflammation pain. Additionally, Ketorolac hydrochloride serves as a DDX3 inhibitor, making it pertinent for research in cancer therapies.

Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.

Ketorolac (RS37619) hemicalcium is a nonselective COX inhibitor with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This non-steroidal anti-inflammatory drug (NSAID) is used as a 0.5% ophthalmic solution for researching allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, it is a DDX3 inhibitor applicable in cancer research [1] [4].

Bromfenac can be used in the research of ocular inflammation that is a potent and orally active COX inhibitor with IC50 values of 5.56 and 7.45 nM for COX-1 and COX-2, respectively [1].

Bromfenac Sodium (AHR 10282R) is a nonsteroidal anti-inflammatory drug (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.

Abicipar pegol (AGN-150998, MP0112), an anti-VEGF DARPin molecule, is a novel class of small ankyrin repeat domain-containing proteins designed for high specificity and affinity targeting. This compound effectively inhibits angiogenesis and vascular permeability, and has been applied in ocular inflammation-related disease studies through intravitreal injections, significantly reducing mean retinal thickness and leakage area [1] [2].

Interphotoreceptor retinoid-binding protein (1-20) (IRBP1-20), a dodecapeptide fragment of retinoid-binding protein 3, plays a crucial role in pigment regeneration by facilitating the transport of retinol and retinal between photoreceptor cells and the retinal pigment epithelium. It has been utilized to provoke autoimmune uveoretinitis in C57BL/6 mice, possessing the H-2b haplotype. Furthermore, IRBP1-20 at a concentration of 3 µM enhances the secretion of IL-4, IL-5, and IL-6 from primary mouse spleen lymphocytes. Immunization and subsequent rechallenge with IRBP1-20 lead to increased ear swelling, inflammation of ocular blood vessels, infiltration by immune cells, damage to the photoreceptor layer, and retinal detachment in IFN-γ-deficient mice.

TAT-N24 is a cell-penetrating TAT peptide that functions as a p55PIK signaling inhibitor. By suppressing the HIF-1α NF-κB signaling pathway in corneal sutures (CS), TAT-N24 can treat corneal neovascularization (CNV) and ocular inflammation. Additionally, TAT-N24 inhibits the formation of corneal neovascularization.